# US 8,999,338 B2 · Method for diagnosis for multiple sclerosis involving anti1-receptor antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,999,338 B2
- Document ID: US8999338B2
- Status: Granted
- Kind: B2
- Application number: 13/640,073
- Filed: 2011-04-12
- Published: 2013-03-14
- Granted: 2015-04-07
- Earliest claimed: 2010-04-12
- Assignees: Celltrend GmbH
- Applicants: Harald Heidecke
- Inventors: Harald Heidecke
- Web page: https://patentgrep.com/patent/US8999338B2

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a method for diagnosis of multiple sclerosis (MS) wherein, presence or absence of an anti-AT1 receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease.

## Claims

### Claim 1

A method for complementing the diagnosis of multiple sclerosis in a patient suspected to have multiple sclerosis based on diagnostic criteria comprising obtaining a sample from the patient and performing an immunoassay on the sample to determine the presence or absence of an anti-AT1 receptor antibody in the sample, wherein the presence of an anti-AT1-receptor antibody is indicative of multiple sclerosis, and wherein the patient is human.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said multiple sclerosis is selected from the group consisting of multiple sclerosis, relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, progressive relapsing multiple sclerosis, and borderline forms of multiple sclerosis including Devic's disease, Balo concentric sclerosis, Schilder's diffuse sclerosis, and Marburg multiple sclerosis.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the determination of presence or absence of an anti-AT1 receptor antibody is done by detecting at least one of the antibodies selected from the group consisting of IgA-antibody, IgG-antibody, and IgM-antibody.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the IgG-antibody is detected and is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the immunoassay is selected from the group consisting of immunoprecipitation, enzyme immunoassay (EIA), radioimmunoassay (RIA), fluorescent immunoassay, a chemiluminescent assay, an agglutination assay, nephelometric assay, turbidimetric assay, a Western blot, a competitive immunoassay, a noncompetitive immunoassay, a homogeneous immunoassay, a heterogeneous immunoassay, a bioassay, and a reporter-assay optionally comprising a Luciferase-Assay.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said immunoassay is an ELISA.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said multiple sclerosis is multiple sclerosis with relapses.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said anti-AT1-receptor antibodies are a biomarker for disease activity in multiple sclerosis with relapses.

### Claim 9

A method for complementing the diagnosis of multiple sclerosis in a patient suspected to have multiple sclerosis based on diagnostic criteria comprising obtaining serum from the patient and performing a cellular ELISA on the serum to determine the presence or absence of an anti-AT1 receptor antibody in the serum, wherein the presence of an anti-AT1-receptor antibody is indicative of multiple sclerosis, and wherein the patient is human.

### Claim 10 (depends on 1)

The method according to claim 1, wherein an AT1 receptor peptide is used to determine the presence or absence of an anti-AT1 receptor antibody in the sample.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said method comprises utilizing an immunological test kit, wherein said kit comprises an AT1-receptor peptide.